nach oben

Erschienen in:

01.05.2008 | ORIGINAL CONTRIBUTION

Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening

verfasst von: Gurpreet S. Bhamra, Derek J. Hausenloy, Sean M. Davidson, Richard D. Carr, Marta Paiva, Abigail M. Wynne, Mihaela M. Mocanu, Prof. Derek M. Yellon

Erschienen in: Basic Research in Cardiology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

In the majority of studies, metformin has been demonstrated to cardioprotect diabetic patients, the mechanism of which is unclear. We hypothesized that metformin cardioprotects the ischemic heart through the Akt-mediated inhibition of mitochondrial permeability transition pore (mPTP) opening.

Materials and methods

Isolated perfused hearts from normoglycemic Wistar or from diabetic Goto-Kakizaki (GK) rats (N ≥ 6/group) were subjected to 35 min ischemia and 120 min of reperfusion. Metformin (50 µmol/l) was added for 15 min at reperfusion, alone or with LY294002 (15 µmol/l), a PI3K inhibitor. Infarct size and Akt phosphorylation were measured. Furthermore, the effect of metformin on mPTP opening in adult cardiomyocytes isolated from both strains was determined.

Results

Metformin reduced infarct size in both Wistar (35 ± 2.7% metformin vs. 62 ± 3.0% control: P < 0.05) and GK hearts (43 ± 4.7% metformin vs. 60 ± 3.8% control: P < 0.05). This protection was accompanied by a significant increase in Akt phosphorylation. LY294002 abolished the metformin-induced Akt phosphorylation and the infarct-limiting effect of metformin in Wistar (61 ± 6.7% metformin + LY294002 vs. 35 ± 2.7% metformin: P < 0.05) and GK rats (56 ± 5.7% metformin + LY294002 vs. 43 ± 4.7% metformin: P < 0.05). In addition, metformin significantly inhibited mPTP opening and subsequent rigor contracture in both Wistar and GK cardiomyocytes subjected to oxidative stress, in a LY-sensitive manner.

Conclusions

We report that metformin given at the time of reperfusion reduces myocardial infarct size in both the non-diabetic and diabetic heart and this protective effect is mediated through PI3K and is associated with Akt phosphorylation. Furthermore, cardioprotection appears to be executed through a PI3K-mediated inhibition of mPTP opening. These findings may explain in part the cardioprotective properties of metformin observed in clinical studies of diabetic patients.

(1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854–865

Abdallah Y, Gkatzoflia A, Gligorievski D, Kasseckert S, Euler G, Schluter KD, Schafer M, Piper HM, Schafer C (2006) Insulin protects cardiomyocytes against reoxygenation-induced hypercontracture by a survival pathway targeting SR Ca2+ storage. Cardiovasc Res 70:346–353PubMedCrossRef

Alserius T, Hammar N, Nordqvist T, Ivert T (2006) Risk of death or acute myocardial infarction 10 years after coronary artery bypass surgery in relation to type of diabetes. Am Heart J 152:599–605PubMedCrossRef

An D, Kewalramani G, Chan JK, Qi D, Ghosh S, Pulinilkunnil T, Abrahani A, Innis SM, Rodrigues B (2006) Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3. Diabetologia 49:2174–2184PubMedCrossRef

Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M (2005) Postconditioning inhibits mitochondrial permeability transition. Circulation 111:194–197PubMedCrossRef

Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334:574–579PubMedCrossRef

Batandier C, Guigas B, Detaille D, El Mir M, Fontaine E, Rigoulet M, Leverve XM (2006) The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr 38:33–42PubMedCrossRef

Bopassa JC, Ferrera R, Gateau-Roesch O, Couture-Lepetit E, Ovize M (2005) PI 3-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. Cardiovasc Res 69:178–185PubMedCrossRef

Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W, Furnsinn C (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53:1052–1059PubMedCrossRef

10.

Calafiore AM, Di Mauro M, Di Giammarco G, Contini M, Vitolla G, Iaco AL, Canosa C, D’Alessandro S (2003) Effect of diabetes on early and late survival after isolated first coronary bypass surgery in multivessel disease. J Thorac Cardiovasc Surg 125:144–154PubMedCrossRef

11.

Charlon V, Boucher F, Mouhieddine S, de Leiris JD (1988) Reduction of myocardial infarct size by metformin in rats submitted to permanent left coronary artery ligation. Diabete Metab 14:591–595

12.

Davidson SM, Hausenloy D, Duchen MR, Yellon DM (2006) Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 38:414–419PubMedCrossRef

13.

De Giorgi F, Lartigue L, Bauer MK, Schubert A, Grimm S, Hanson GT, Remington SJ, Youle RJ, Ichas F (2002) The permeability transition pore signals apoptosis by directing Bax translocation and multimerization. FASEB J 16:607–609PubMed

14.

Detaille D, Guigas B, Chauvin C, Batandier C, Fontaine E, Wiernsperger N, Leverve X (2005) Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 54:2179–2187PubMedCrossRef

15.

El Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275:223–228PubMedCrossRef

16.

Griffiths EJ, Halestrap AP (1995) Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 307(Pt 1):93–98PubMed

17.

Guigas B, Detaille D, Chauvin C, Batandier C, De Oliveira F, Fontaine E, Leverve X (2004) Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem J 382:877–884PubMedCrossRef

18.

Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRef

19.

Hausenloy DJ, Yellon DM (2003) The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35:339–341PubMedCrossRef

20.

Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia–reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 61:448–460PubMedCrossRef

21.

Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM (2002) Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 55:534–543PubMedCrossRef

22.

Hausenloy D, Mocanu M, Yellon D (2004) Cross-talk between the survival kinases during reperfusion in ischaemic preconditioning. Cardiovasc J S Afr 15:S11

23.

Hausenloy DJ, Yellon DM, Mani-Babu S, Duchen MR (2004) Preconditioning protects by inhibiting the mitochondrial permeability transition. Am J Physiol Heart Circ Physiol 287:H841–H849PubMedCrossRef

24.

Huser J, Blatter LA (1999) Fluctuations in mitochondrial membrane potential caused by repetitive gating of the permeability transition pore. Biochem J 343(Pt 2):311–317PubMedCrossRef

25.

Huser J, Rechenmacher CE, Blatter LA (1998) Imaging the permeability pore transition in single mitochondria. Biophys J 74:2129–2137PubMedCrossRef

26.

Jacobson J, Duchen MR (2002) Mitochondrial oxidative stress and cell death in astrocytes—requirement for stored Ca2+ and sustained opening of the permeability transition pore. J Cell Sci 115:1175–1188PubMed

27.

Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP (2003) Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 549:513–524PubMedCrossRef

28.

Johnson JA, Majumdar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244–2248PubMedCrossRef

29.

Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ (2004) Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113:1535–1549PubMed

30.

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443PubMedCrossRef

31.

Kao J, Tobis J, McClelland RL, Heaton MR, Davis BR, Holmes DR Jr., Currier JW (2004) Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 93:1347–1350PubMedCrossRef

32.

Kawabata H, Ishikawa K (2003) Cardioprotection by metformin is abolished by a nitric oxide synthase inhibitor in ischemic rabbit hearts. Hypertens Res 26:107–110PubMedCrossRef

33.

Kim JS, Jin Y, Lemasters JJ (2006) Reactive oxygen species, but not Ca2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia–reperfusion. Am J Physiol Heart Circ Physiol 290:H2024–H2034PubMedCrossRef

34.

King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMedCrossRef

35.

Kirpichnikov D, McFarlane SI, Sowers JR (2002) Metformin: an update. Ann Intern Med 137:25–33PubMed

36.

Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD (1995) High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270:17513–17520PubMedCrossRef

37.

Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, Yano M, Motoshima H, Taguchi T, Matsumura T, Araki E (2006) Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 55:120–127PubMedCrossRef

38.

Legtenberg RJ, Houston RJ, Oeseburg B, Smits P (2002) Metformin improves cardiac functional recovery after ischemia in rats. Horm Metab Res 34:182–185PubMedCrossRef

39.

Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A (2000) Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102:1014–1019PubMed

40.

Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR Jr. (2004) Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 109:476–480PubMedCrossRef

41.

McGuire DK, Emanuelsson H, Granger CB, Magnus OE, Moliterno DJ, White HD, Ardissino D, Box JW, Califf RM, Topol EJ (2000) Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb investigators. Eur Heart J 21:1750–1758PubMedCrossRef

42.

McGuire DK, Newby LK, Bhapkar MV, Moliterno DJ, Hochman JS, Klein WW, Weaver WD, Pfisterer M, Corbalan R, Dellborg M, Granger CB, Van De WF, Topol EJ, Califf RM (2004) Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 147:246–252PubMedCrossRef

43.

Mehenni H, Lin-Marq N, Buchet-Poyau K, Reymond A, Collart MA, Picard D, Antonarakis SE (2005) LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes. Hum Mol Genet 14:2209–2219PubMedCrossRef

44.

Mensah K, Mocanu MM, Yellon DM (2005) Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 45:1287–1291PubMedCrossRef

45.

Miki Oliveira PJ, Esteves TC, Seica R, Moreno AJ, Santos MS (2004) Calcium-dependent mitochondrial permeability transition is augmented in the kidney of Goto-Kakizaki diabetic rat. Diabetes Metab Res Rev 20:131–136CrossRef

46.

Miki T, Miura T, Tanno M, Nishihara M, Naitoh K, Sato T, Takahashi A, Shimamoto K (2007) Impairment of cardioprotective PI3K–Akt signaling by post-infarct ventricular remodeling is compensated by an ERK-mediated pathway. Basic Res Cardiol 102(2):163–170PubMedCrossRef

47.

Oliveira PJ, Seica R, Coxito PM, Rolo AP, Palmeira CM, Santos MS, Moreno AJ (2003) Enhanced permeability transition explains the reduced calcium uptake in cardiac mitochondria from streptozotocin-induced diabetic rats. FEBS Lett 554:511–514PubMedCrossRef

48.

Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348(Pt 3):607–614PubMedCrossRef

49.

Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M (2005) Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28:888–894PubMedCrossRef

50.

Ren J, Dominguez LJ, Sowers JR, Davidoff AJ (1999) Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Diabetes 48:2059–2065PubMedCrossRef

51.

Rosen P, Wiernsperger NF (2006) Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress. Diabetes Metab Res Rev 22:323–330PubMedCrossRef

52.

Ruiz-Meana M, Garcia-Dorado D, Miro-Casas E, Abellan A, Soler-Soler J (2006) Mitochondrial Ca(2+) uptake during simulated ischemia does not affect permeability transition pore opening upon simulated reperfusion. Cardiovasc Res 71:715–724PubMedCrossRef

53.

Thourani VH, Weintraub WS, Stein B, Gebhart SS, Craver JM, Jones EL, Guyton RA (1999) Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 67:1045–1052PubMedCrossRef

54.

Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM (2005) Preconditioning the diabetic heart: the importance of akt phosphorylation. Diabetes 54:2360–2364PubMedCrossRef

55.

Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR (2001) Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 276:48627–48630PubMedCrossRef

56.

Verma S, McNeill JH (1994) Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts. Am J Physiol 266:H714–H719PubMed

57.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167–1174PubMed

Titel: Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening
verfasst von: Gurpreet S. Bhamra
Derek J. Hausenloy
Sean M. Davidson
Richard D. Carr
Marta Paiva
Abigail M. Wynne
Mihaela M. Mocanu
Prof. Derek M. Yellon
Publikationsdatum: 01.05.2008
Verlag: D. Steinkopff-Verlag
Erschienen in: Basic Research in Cardiology / Ausgabe 3/2008
Print ISSN: 0300-8428
Elektronische ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-007-0691-y

Neu im Fachgebiet Kardiologie

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening

Abstract

Background

Materials and methods

Results

Conclusions

Neu im Fachgebiet Kardiologie

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Update Kardiologie

Springer Medizin

Abstract

Background

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Regulation of cell–matrix contacts and β-catenin signaling in VSMC by integrin-linked kinase: implications for intimal thickening

Stem cell factor/c-kit signaling mediated cardiac stem cell migration via activation of p38 MAPK

Heart spotting

Age-dependent endothelial dysfunction is associated with failure to increase plasma nitrite in response to exercise

Adenosine: trigger and mediator of cardioprotection

Myocardial adaptation of energy metabolism to elevated preload depends on calcineurin activity

Neu im Fachgebiet Kardiologie

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Update Kardiologie